Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study
Lin Shen, Yifan Yang, Lei Lü, Oscar Hou In Chou, Quinncy Lee, Tong Liu, Guoliang Li, Shuk Han Cheng, Gary Tse, Jiandong Zhou
This paper uses Mendelian randomization to find that SGLT2 and DPP4 inhibition are associated with reduced prostate cancer risk, but GLP1R agonism is not.
medRxiv · Sep 15, 2024 · PreprintGenetic & Genomic Medicine